Altan, Mehmet
Kidwell, Kelley M.
Pelekanou, Vasiliki
Carvajal-Hausdorf, Daniel E.
Schalper, Kurt A.
Toki, Maria I.
Thomas, Dafydd G.
Sabel, Michael S.
Hayes, Daniel F.
Rimm, David L.
Article History
Received: 16 May 2018
Accepted: 13 November 2018
First Online: 10 December 2018
Competing interests
: D.L.R. is a consultant/advisor to Astra Zeneca, Agendia, Agilent, Bethyl Labs, Biocept, BMS, Cell Signaling Technology, Cepheid, Merck, OptraScan, Perkin Elmer, and Ultivue. Holds equity in PixelGear. Astra Zeneca, Cepheid, Navigate/Novartis, Gilead Sciences, Ultivue, and Perkin Elmer funds research in Rimm’s lab. The remaining authors declare no competing interests.